# US 2003/0211990 A1 · Neural regeneration peptides and methods for their use in treatment of brain damage

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211990 A1
- Document ID: US20030211990A1
- Status: Published application
- Kind: A1
- Application number: 10/225,838
- Filed: 2002-08-22
- Published: 2003-11-13
- Earliest claimed: 2001-08-24
- Assignees: Neuren Pharmaceuticals Limited
- Inventors: Frank Sieg; Paul Hughes
- Web page: https://patentgrep.com/patent/US20030211990A1

## CPC

- C07K 14/4756: {Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention discloses a family of neuronal migration-inducing, proliferation-promoting and neurite outgrowth promoting factors, termed NRP compounds, and provides compositions and methods for the use of NRP compounds in the treatment of brain injury and neurodegenerative disease. NRP-1 compounds induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient.

## Claims

### Claim 1

A neural regeneration peptide (NRP) compound comprising at least one amino acid sequence comprising at least one [A]PG[R,S] domain, and having at least one biological effect selected from the group consisting of neuronal migration, neural proliferation, neural outgrowth promoting activities and neural survival.

### Claim 2 (depends on 1)

The NRP of claim 1, further comprising at least one additional amino acid domain selected from the group consisting of [A]PG[R,S], PE, [A,G]RR and ARG.

### Claim 3 (depends on 1)

The NRP of claim 1, wherein said peptide has a molecular weight of about 0.8 kD to about 2.7kD.

### Claim 4 (depends on 1)

The NRP of claim 1, wherein said peptide has an isoelectric point between about 6.5 and about 10.

### Claim 5 (depends on 1)

The NRP of claim 1, having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO: 21, SEQ ID No: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26:

### Claim 6

A nucleotide sequence encoding an NRP selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, and SEQ ID NO: 19.

### Claim 7 (depends on 6)

A nucleic acid encoding an NRP, wherein said nucleotide sequence differs from the nucleotide sequence of claim 6 only by virtue of redundancy in the genetic code.

### Claim 8

A method for promoting neural regeneration, comprising the step of delivering to a neural tissue, a pharmacologically effective amount of an NRP compound.

### Claim 9 (depends on 8)

The method of claim 8, wherein said neural regeneration is selected from the group consisting of neural survival, neural proliferation, neural migration and neurite outgrowth.

### Claim 10 (depends on 1, 8)

The method of claim 8, wherein said NRP comprises a peptide of claim 1.

### Claim 11 (depends on 2, 8)

The method of claim 8, wherein said NRP comprises a peptide of claim 2.

### Claim 12 (depends on 5, 8)

The method of claim 8, wherein said NRP comprises a peptide of claim 5.

### Claim 13 (depends on 6, 8)

The method of claim 8, wherein said NRP is encoded by a nucleic acid of claim 6.

### Claim 14 (depends on 6, 8)

The method of claim 8, wherein said NRP is encoded by a nucleic acid of claim 6 or a nucleic acid having a sequence that differs from that of a nucleic acid of claim 6 only by the redundancy of the genetic code.

### Claim 15 (depends on 6)

A nucleic acid molecule encoding an NRP, said nucleic acid having at least 85% nucleotide sequence identity over the entire sequence to a nucleotide sequence of claim 6.

### Claim 16 (depends on 6)

An expression vector comprising a nucleotide sequence of claim 6, wherein said expression vector can express an NRP.

### Claim 17 (depends on 16)

The expression vector of claim 16, wherein the vector is a plasmid.

### Claim 18 (depends on 16)

The expression vector of claim 16, wherein the vector is a viral vector.

### Claim 19 (depends on 16)

A host cell containing the expression vector of claim 16.

### Claim 20 (depends on 19)

The host cell of claim 19, wherein the cell is prokaryotic.

### Claim 21 (depends on 19)

The host cell of claim 19, wherein the cell is eukaryotic.

### Claim 22 (depends on 6)

The nucleotide sequence of claim 6 SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, or SEQ ID NO: 19., wherein “t” is replaced by “u”.

### Claim 23

A nucleotide sequence comprising a complementary strand to a strand selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, and SEQ ID NO: 19.

### Claim 24 (depends on 23)

The nucleotide sequence of claim 23, said sequence at least 15 base pairs in length, and hybridizes under stringent hybridization conditions to a genomic DNA encoding an NRP.

### Claim 25

A polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity over the entire sequence to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26.

### Claim 26 (depends on 8)

The method of claim 8, wherein said neural tissue is present in an animal's basal ganglia.

### Claim 27 (depends on 26)

The method of claim 26, wherein said neural tissue is at risk for degeneration due to Parkinson's Disease, Alzheimer's disease, hypoxia, eschemia or Huntington's Disease.

### Claim 28

A method for treating a neurological condition characterized by neural degeneration in an organism, comprising the step of administering to affected nerves of said organism, a pharmacologically effective amount of an NRP compound.

### Claim 29 (depends on 28)

The method of claim 28, wherein said neurological condition is selected from the group consisting of Parkinson's Disease, Alzheimer's Disease, hypoxia, eschemia, and Huntington's Disease.

### Claim 30

A method for inducing neuronal proliferation and/or neuronal migration in a neuron, comprising administering an effective amount of an NRP compound to said neuron.

### Claim 31

A method for promoting neurite outgrowth in a neuron, comprising administering an effective amount of an NRP compound to said neuron.

### Claim 32

A method for promoting neuronal survival, comprising administering an effective amount of an NRP compound to said neuron.

### Claim 33

A method for inducing neuronal proliferation and/or neuronal migration in a neuron, comprising administering an effective amount of an NRP compound to said neuron.

### Claim 34 (depends on 33)

The method of claim 33, wherein said neuron is present within a living animal.

### Claim 35 (depends on 33)

The method of claim 33, wherein said neuron is not within the body of said animal.

### Claim 36 (depends on 33)

The method of claim 33, wherein said neuron is present within the central nervous system of said animal.

### Claim 37 (depends on 35)

The method of claim 35, wherein said neuron is not within the body of said animal.

### Claim 38

A method of treating a patient having a spinal cord injury comprising administering an effective amount of an NRP compound to said patient.

### Claim 39 (depends on 5)

The peptide of claim 5, wherein the amino acid sequence of claim 5 differs from an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 or SEQ ID NO: 26 by virtue of a conservative amino acid substitution.

### Claim 40

A method for determining the presence of an NRP, comprising the steps of:
(a) providing a tissue culture system comprising:
1. a tissue culture substrate;
2. a cortical tissue placed on said substrate; and
3. a thalamic tissue placed on said substrate; said cortical and thalamic tissues placed at least 2 mm apart;
(b) incubating said cortical tissue and said thalamic tissue in the presence of a test molecule;
(c) detecting one or more biological effect of neuronal survival, neuronal proliferation, neuronal migration or neurite outgrowth;
and
(d) comparing said observed biological effect in the presence of said test molecule to the observed biological effect observed in the absence of said test molecule.

### Claim 41 (depends on 40)

The method of claim 40, wherein said cortical tissue and said thalamic tissues are from a rat.

### Claim 42 (depends on 40)

The method of claim 40, wherein said test molecule is an NRP compound.

### Claim 43

A method for determining the pharmacological efficacy of an NRP, comprising the steps of:
(a) providing a tissue culture system comprising:
1. a tissue culture substrate;
2. a cortical tissue placed on said substrate; and
3. a thalamic tissue placed on said substrate; said cortical and thalamic tissues placed at least 2 mm apart;
(b) incubating said cortical tissue and said thalamic tissue in the presence of a test molecule;
(c) detecting one or more biological effect of neuronal survival, neuronal proliferation, neuronal migration or neurite outgrowth;
and
(d) comparing said observed biological effect in the presence of said test molecule to the observed biological effect observed in the absence of said test molecule.

### Claim 44

A method for comparing the efficacy of a test molecule, comprising the steps of:
(a) providing a tissue culture system comprising:
1. a tissue culture substrate;
2. a cortical tissue placed on said substrate; and
3. a thalamic tissue placed on said substrate; said cortical and thalamic tissues placed at least 2 mm apart;
(b) incubating said cortical tissue and said thalamic tissue in the presence of a test molecule;
(c) detecting one or more biological effect of neuronal survival, neuronal proliferation, neuronal migration or neurite outgrowth; and
(d) comparing said observed biological effect in the presence of said test molecule to the observed biological effect observed in the presence of a known amount of an NRP compound.

### Claim 45

A test kit for determining the presence of NRP-like activity, comprising the steps of:
(a) providing a tissue culture system comprising:
1. a tissue culture substrate;
2. a cortical tissue placed on said substrate; and
3. a thalamic tissue placed on said substrate; said cortical and thalamic tissues placed at least 2 mm apart;
(b) incubating said cortical tissue and said thalamic tissue in the presence of a test molecule;
(c) detecting one or more biological effect of neuronal survival, neuronal proliferation, neuronal migration or neurite outgrowth; and
(d) comparing said observed biological effect in the presence of said test molecule to the observed biological effect observed in the absence of said test molecule.
